日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Direct observation and quantification of single nanocondensates of the low complexity domain of TDP-43

对TDP-43低复杂度结构域的单个纳米凝聚体进行直接观察和定量分析

Houx, Justin; Cussac, Julian; Copie, Thomas; Gambin, Yann; Sierecki, Emma

Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center

伊马替尼新辅助治疗对局部晚期隆突性皮肤纤维肉瘤行莫氏手术有效吗?一家皮肤肿瘤转诊中心的经验

Bota-Llorca, A; Llombart-Cussac, B; Serra-Guillén, C; López-Guerrero, J A; Traves, V; Sanmartín-Martínez, J J; Requena, C; Nagore, E; Padilla-Esquivel, J; Millán-Esteban, D; Mayo, F; Sanmartín, O

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

新辅助治疗期间残余病灶(RD)生物学和基因表达变化对HER2阳性早期乳腺癌(EBC)患者的预后价值

Fernandez-Martinez, A; Tanioka, M; Ahn, S G; Zagami, P; Pascual, T; Rediti, M; Tang, G; Hoadley, K A; Venet, D; Rashid, N U; Spears, P A; Di Cosimo, S; de Azambuja, E; Choudhury, A; Rastogi, P; Islam, M N; Cortes, J; Llombart-Cussac, A; Swain, S M; Sotiriou, C; Prat, A; Perou, C M; Carey, L A

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

阿特珠单抗联合紫杉醇和贝伐珠单抗一线治疗晚期三阴性乳腺癌:ATRACTIB II期试验

Gion, María; Blancas, Isabel; Cortez-Castedo, Patricia; Cortés-Salgado, Alfonso; Marmé, Frederik; Blanch, Salvador; Morales, Serafín; Díaz, Nieves; Calvo-Plaza, Isabel; Recalde, Sabela; Martínez-Bueno, Alejandro; Ruiz-Borrego, Manuel; Llabrés, Elisenda; Taberner, María Teresa; de Laurentiis, Michelino; García-Vicente, Silvia; Guerrero, José Antonio; Boix, Olga; Rodríguez-Morató, Jose; Sampayo-Cordero, Miguel; Antonarelli, Gabriele; Pérez-García, José Manuel; Cortés, Javier; Llombart-Cussac, Antonio

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

Patritumab deruxtecan治疗实体瘤脑膜转移性疾病:TUXEDO-3 II期试验

Preusser, Matthias; Garde-Noguera, Javier; García-Mosquera, Juan José; Gion, María; Greil, Richard; Arumi, Miriam; Ruiz-Borrego, Manuel; Llombart-Cussac, Antonio; Valero, María; Cortés, Javier; Campolier, Marta; Guerrero, José Antonio; González-Alonso, Paula; Jiménez-Cortegana, Carlos; Rodríguez-Morató, Jose; Vaz-Batista, Marta; Oberndorfer, Felicitas; Marhold, Maximilian; Berghoff, Anna Sophie; Furtner, Julia; Fuereder, Thorsten; Bartsch, Rupert

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial

在激素受体阳性/人表皮生长因子受体2阴性的晚期乳腺癌患者中,二线内分泌治疗联合或不联合帕博西尼再挑战:PALMIRA试验

Llombart-Cussac, Antonio; Harper-Wynne, Catherine; Perelló, Antonia; Hennequin, Audrey; Fernández-Ortega, Adela; Colleoni, Marco; Marín, Sara; Quiroga, Vanesa; Medioni, Jacques; Iranzo, Vega; Wheatley, Duncan; Del Barco Berrón, Sonia; Antón, Antonio; Dobi, Erion; Ruiz-Borrego, Manuel; Alcalá-López, Daniel; Pérez-Escuredo, Jhudit; Antonarelli, Gabriele; Sampayo-Cordero, Miguel; Pérez-García, José Manuel; Cortés, Javier

Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial

预防 HER2 阴性晚期乳腺癌患者接受 sacituzumab govitecan 治疗后出现中性粒细胞减少症和腹泻(PRIMED):一项开放标签、单臂 II 期试验

Pérez-García, José Manuel; Gion, María; Ruiz-Borrego, Manuel; Blancas, Isabel; López-Miranda, Elena; Blanch, Salvador; Recalde, Sabela; Rendo, Cristina Reboredo; González, Xavier; Ancizar, Nerea; Morales, Serafin; Cortez, Patricia; Piwowarska, Zuzanna; Shimizu, Eileen; Guerrero, José Antonio; Sampayo-Cordero, Miguel; Martínez-Bueno, Alejandro; Cortés, Javier; Llombart-Cussac, Antonio

Analysis of effector/memory regulatory T cells from arrhythmogenic cardiomyopathy patients identified IL-32 as a novel player in ACM pathogenesis.

对致心律失常性心肌病患者的效应/记忆调节性 T 细胞进行分析,发现 IL-32 是 ACM 发病机制中的新角色

Soussi Salwa, Maione Angela Serena, Lefèvre Lise, Pizzinat Nathalie, Iacovoni Jason, Gonzalez-Fuentes Ignacio, Cussac Daniel, Iengo Lara, Santin Yohan, Tundo Fabrizio, Tondo Claudio, Pompilio Giulio, Parini Angelo, Douin-Echinard Victorine, Sommariva Elena

Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis

曲妥珠单抗德鲁替康治疗HER2阳性伴活动性脑转移乳腺癌的三项研究的患者水平汇总分析结果

Bartsch, R; Pérez-García, J M; Furtner, J; Berghoff, A S; Marhold, M; Starzer, A M; Hughes, M; Kabraji, S; Sammons, S; Anders, C; Murthy, R K; Van Swearingen, A E D; Pereslete, A; Gion, M; Vaz Batista, M; Braga, S; Pinto, P B C; Sampayo-Cordero, M; Llombart-Cussac, A; Preusser, M; Cortés, J; Lin, N U

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial

在PARSIFAL试验中,对帕博西尼联合氟维司群或来曲唑治疗内分泌敏感、激素受体阳性/HER2阴性晚期乳腺癌患者进行了延长随访。

Llombart-Cussac, A; Pérez-García, J M; Bellet, M; Dalenc, F; Gil-Gil, M; Ruiz-Borrego, M; Gavila, J; Schmid, P; Zamora, P; Wheatley, D; Martínez-de Dueñas, E; Amillano, K; Di Cosimo, S; Anton, A; Cottu, P; Shimizu, E; Fernandez, M; Sampayo-Cordero, M; Cortés, J